Amarin Corporation plc: Amarin Partner EddingPharm Receives Regulatory Approval for Vascepa® (Icosapent Ethyl) in Mainland China

-- VASCEPA Approved by the National Medical Products Administration (NMPA) as an Adjunct to Diet to Reduce Triglyceride Levels in Adult Patients with Severe Hypertriglyceridemia (= 500 mg/dL) -- --

Related Keywords

China ,Ireland ,United Arab Emirates ,Dublin ,New Jersey ,United States ,Finland ,Lebanon ,Switzerland ,Sweden ,Canada ,Chinese ,Lisa Defrancesco ,Mark Marmur ,Rebecca Xu ,Steven Ketchum ,Environmental Sciences ,European Union ,Drug Administration ,Nasdaq ,Amarin Corporation ,Clinical Development ,Exchange Commission ,World Heart Federation Fact Sheet ,Research Development ,National Medical Products Administration ,Committee Of The Report On Cardiovascular Health ,Cardiovascular Health ,National Reimbursement Drug Listing ,China National Medical Products Administration ,World Heart Federation ,Reduce Triglyceride Levels ,Adult Patients ,Severe Hypertriglyceridemia ,Pharm Now Working Towards Preparing ,Commercial Launch ,Mainland China Expected ,Mainland China ,Chief Scientific Officer ,Vice President ,Healthy China ,United Arab ,Private Securities Litigation Reform Act ,Securities Act ,Writing Committee ,Cardiovascular Disease ,Amarin ,Corporation ,Partner ,Ddingpharm ,Eceives ,Egulatory ,Approval ,Vascepa ,Icosapent ,Methyl ,Mainland ,